An all-virtual clinical trial to assess a heart failure drug
- PMID: 35301453
- PMCID: PMC8929242
- DOI: 10.1038/s41569-022-00691-z
An all-virtual clinical trial to assess a heart failure drug
Abstract
The CHIEF-HF trial investigators employed a novel all-virtual study design to show that canagliflozin significantly reduces symptom burden in patients with heart failure.
Comment on
-
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.Nat Med. 2022 Apr;28(4):809-813. doi: 10.1038/s41591-022-01703-8. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228753 Free PMC article. Clinical Trial.
References
Original article
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
